Modus Therapeutics to Showcase New Sevuparin Research in CKD
Modus Therapeutics will present new research findings on its investigational drug sevuparin for chronic kidney disease (CKD) with anemia at the 32nd Symposium on Glycosaminoglycans (GAGs), an exclusive scientific meeting running from 18–20 September at Villa Vigoni, Italy.
The invitation-only event brings together global experts in GAG science and clinical innovation, highlighting cutting-edge developments in this specialised field.
Joint Research with the University of Brescia
The presentation will be delivered by Professor Maura Poli of the University of Brescia, showcasing collaborative data generated between Modus and Brescia.
The findings build upon results previously unveiled at the European Hematology Association (EHA) 2025 congress, where sevuparin demonstrated improvements in both anemia and kidney function within a validated CKD model.
Preclinical studies have also shown that sevuparin can reduce fibrosis and markers of kidney injury. Notably, benefits were observed both as a standalone treatment and in combination with erythropoietin (EPO).
These outcomes align with sevuparin’s hepcidin-lowering mechanism of action, strengthening its potential role in the treatment of CKD-related anemia.
Advancing the Clinical Programme
The new data arrive as Modus advances its clinical programme. Part 1 of the ongoing phase 2a trial in CKD patients with anemia has been successfully completed. Part 2, designed to establish proof-of-concept for the therapy, is scheduled to begin in the fourth quarter of 2025.
Sevuparin has already attracted attention across multiple international forums, with data recently presented at both BioIron and EHA 2025. Together, these findings continue to highlight sevuparin’s differentiated profile in the treatment landscape for CKD-related anemia.
A Unique Approach with Glycosaminoglycans
Sevuparin is derived from glycosaminoglycans, a unique carbohydrate (sugar)-based class of biomolecules with broad biological roles.
According to the company’s CEO, Modus is pioneering the development of medicines from this group, with the aim of addressing diseases characterised by inflammation and iron/hepcidin dysregulation.
The CEO explained that the research that they and their academic collaborators have conducted shows that sevuparin can modulate key drivers of inflammation and iron regulation.
What’s more, to receive recognition at such a prestigious international GAG summit underlines the molecule’s distinct clinical profile and the promise it holds as they move into the next phase of development.
Conclusion
The spotlight on sevuparin at the 32nd Symposium on Glycosaminoglycans marks another important step in Modus Therapeutics’ mission to develop innovative treatments for patients with chronic kidney disease and anemia.
With encouraging preclinical and clinical data, a progressing phase 2 programme, and growing recognition among global experts, sevuparin is shaping up as a potential game-changer in tackling the complex interplay of inflammation, iron regulation, and kidney function.
News Credits: CKD to be presented at global GAG symposium
Things you may also like: